AVXL — Anavex Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $327.91m
- $225.33m
- 30
- 20
- 32
- 15
Annual cashflow statement for Anavex Life Sciences, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -37.9 | -48 | -47.5 | -43 | -46.4 |
| Non-Cash Items | 8.23 | 18.4 | 17.2 | 9.44 | 11.5 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.706 | 5.36 | 2.5 | 2.75 | -4.22 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -30.4 | -24.2 | -27.8 | -30.8 | -39 |
| Financing Cash Flow Items | -5.55 | -0.707 | 0 | — | -2.71 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 153 | 21.3 | 29.7 | 12 | 9.43 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 123 | -2.95 | 1.87 | -18.8 | -29.6 |